These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 22297638)
21. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma. Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936 [TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical assessment of mitotic count in uveal melanoma. Angi M; Damato B; Kalirai H; Dodson A; Taktak A; Coupland SE Acta Ophthalmol; 2011 Mar; 89(2):e155-60. PubMed ID: 19900200 [TBL] [Abstract][Full Text] [Related]
23. Phosphohistone H3 expression correlates with manual mitotic counts and aids in identification of "hot spots" in fibroepithelial tumors of the breast. Ginter PS; Shin SJ; Liu Y; Chen Z; D'Alfonso TM Hum Pathol; 2016 Mar; 49():90-8. PubMed ID: 26826415 [TBL] [Abstract][Full Text] [Related]
24. Prognostic factors in head and neck mucosal malignant melanoma. Çomoğlu Ş; Polat B; Çelik M; Şahin B; Enver N; Keleş MN; Sarı ŞÖ Auris Nasus Larynx; 2018 Feb; 45(1):135-142. PubMed ID: 28385366 [TBL] [Abstract][Full Text] [Related]
25. Phosphohistone-H3 and Ki-67 immunostaining in cutaneous pilar leiomyoma and leiomyosarcoma (atypical intradermal smooth muscle neoplasm). Idriss MH; Kazlouskaya V; Malhotra S; Andres C; Elston DM J Cutan Pathol; 2013 Jun; 40(6):557-63. PubMed ID: 23550775 [TBL] [Abstract][Full Text] [Related]
26. Validation of mitosis counting by automated phosphohistone H3 (PHH3) digital image analysis in a breast carcinoma tissue microarray. Dessauvagie BF; Thomas C; Robinson C; Frost FA; Harvey J; Sterrett GF Pathology; 2015 Jun; 47(4):329-34. PubMed ID: 25938351 [TBL] [Abstract][Full Text] [Related]
27. Improving precise counting of mitotic cells in mantle cell lymphoma using phosphohistone H3 (PHH3) antibody. Medani H; Elshiekh M; Naresh KN J Clin Pathol; 2021 Oct; 74(10):646-649. PubMed ID: 32873701 [TBL] [Abstract][Full Text] [Related]
28. Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: a 5-year survival analysis. Donizy P; Kaczorowski M; Leskiewicz M; Zietek M; Pieniazek M; Kozyra C; Halon A; Matkowski R Oncol Rep; 2014 Dec; 32(6):2735-43. PubMed ID: 25310673 [TBL] [Abstract][Full Text] [Related]
29. Value and prognostic significance of mitotic rate in a retrospective series of pT1 cutaneous malignant melanoma patients. Ponti G; Pollio A; Cesinaro AM; Pellacani G; Magnoni C; Seidenari S Cancer Epidemiol; 2012 Jun; 36(3):303-5. PubMed ID: 22153914 [TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Kim YJ; Ketter R; Steudel WI; Feiden W Am J Clin Pathol; 2007 Jul; 128(1):118-25. PubMed ID: 17580279 [TBL] [Abstract][Full Text] [Related]
31. Does mitosis-specific marker phosphohistone H3 help the grading of upper tract urothelial carcinomas in cell blocks? Solomides CC; Birbe RC; Nicolaou N; Bagley D; Bibbo M Acta Cytol; 2012; 56(3):285-8. PubMed ID: 22555531 [TBL] [Abstract][Full Text] [Related]
32. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Ribalta T; McCutcheon IE; Aldape KD; Bruner JM; Fuller GN Am J Surg Pathol; 2004 Nov; 28(11):1532-6. PubMed ID: 15489659 [TBL] [Abstract][Full Text] [Related]
33. Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors. Villani V; Mahadevan KK; Ligorio M; Fernández-Del Castillo C; Ting DT; Sabbatino F; Zhang I; Vangel M; Ferrone S; Warshaw AL; Lillemoe KD; Wargo J; Deshpande V; Ferrone CR Ann Surg Oncol; 2016 Dec; 23(Suppl 5):609-617. PubMed ID: 27020585 [TBL] [Abstract][Full Text] [Related]
34. Predicting short-term recurrence in pituitary adenomas: Phosphohistone-H3 (Ser 10) proves an effective biomarker. Li C; Wei L; Li L; Wang J; Li R; Zhang Q; Zhou D Clin Neuropathol; 2020; 39(2):70-79. PubMed ID: 31724532 [TBL] [Abstract][Full Text] [Related]
35. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Nasr MR; El-Zammar O Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113 [TBL] [Abstract][Full Text] [Related]
36. Mitosis-specific marker phospho-histone H3 in the assessment of mitotic index in uterine smooth muscle tumors: a pilot study. Veras E; Malpica A; Deavers MT; Silva EG Int J Gynecol Pathol; 2009 Jul; 28(4):316-21. PubMed ID: 19483635 [TBL] [Abstract][Full Text] [Related]
37. Identification of Phosphohistone H3 Cutoff Values Corresponding to Original WHO Grades but Distinguishable in Well-Differentiated Gastrointestinal Neuroendocrine Tumors. Kim MJ; Kwon MJ; Kang HS; Choi KC; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Park HC Biomed Res Int; 2018; 2018():1013640. PubMed ID: 29780816 [TBL] [Abstract][Full Text] [Related]
38. Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. Svobodová S; Browning J; MacGregor D; Pollara G; Scolyer RA; Murali R; Thompson JF; Deb S; Azad A; Davis ID; Cebon JS Eur J Cancer; 2011 Feb; 47(3):460-9. PubMed ID: 21115342 [TBL] [Abstract][Full Text] [Related]
39. Phospho-histone-H3 immunostaining for pulmonary carcinoids: impact on clinical appraisal, interobserver correlation, and diagnostic processing efficiency. Laflamme P; Mansoori BK; Sazanova O; Orain M; Couture C; Simard S; Trahan S; Manem V; Joubert P Hum Pathol; 2020 Dec; 106():74-81. PubMed ID: 33007357 [TBL] [Abstract][Full Text] [Related]
40. Value of counting positive PHH3 cells in the diagnosis of uterine smooth muscle tumors. Pang SJ; Li CC; Shen Y; Liu YZ; Shi YQ; Liu YX Int J Clin Exp Pathol; 2015; 8(5):4418-26. PubMed ID: 26191133 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]